IDXX
IDEXX Laboratories, Inc.693.18
-6.95-0.99%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Nuances visits, innovations; reaffirms outlook.
Q&A drilled into U.S. visit splits, pinning wellness weakness on macro pressures in lower-income homes while non-wellness visits—70-75% of diagnostics revenue—held firm with aging pet green shoots. Consumables hit mid-teens via 12% premium installed base growth, including 1,350 global Catalyst placements and InVue consumables tracking $3,500-$5,500 per unit. Reference labs snagged 18% competitive submissions through CancerDx. Software posted double-digit Q4 recurring growth, Velo users up 40% sequentially as an end-market offset. Pricing drew no pushback; volume takes center stage. Management stayed cautious on 2% visit declines. Q&A largely reaffirmed prepared outlook. Non-wellness drives the bus.
Key Stats
Market Cap
55.46BP/E (TTM)
54.93Basic EPS (TTM)
12.62Dividend Yield
0%Recent Filings
8-K
EVP Hunt exits IDEXX
IDEXX Laboratories mutually parted with EVP Global Strategy and Commercial Nimrata Hunt, PhD, eliminating her role effective April 13, 2026; she'll advise until July 13. Separation package totals $2,276,000 in salary continuation, bonuses, and benefits over 104 weeks. Unvested equity forfeits. Position cut signals strategy shift.
10-K
FY2025 results
No financial statements, results, or quarterly metrics disclosed in the 10-K filing. Document details IDEXX Laboratories' Director Deferred Compensation Plan restatement effective October 29, 2025, and Executive Incentive Plan summary for 2026, focusing on deferral elections, vesting, and performance-based bonuses tied to financial and non-financial factors. Lacks topline revenue, profitability, EPS, or segment data for FY2025 ended December 31, 2025, preventing analysis of Q4 momentum. No guidance provided. Plans remain unfunded. Supply chain disruptions could hinder quarterly execution.
8-K
Director Szostak retiring May 2026
IDEXX Laboratories director M. Anne Szostak announced her retirement from the Board effective immediately after the May 12, 2026 Annual Meeting, unrelated to any disagreements. The Board shrank Class III size per bylaws. No board size change, thanks to Michael G. Erickson's prior-announced Class II addition. Smooth transition.
8-K
IDEXX Q4 revenue surges 14%
IDEXX crushed Q4 2025 with $1,091M revenue, up 14% reported, fueled by 12% CAG Diagnostics recurring growth and record 1,900+ inVue Dx placements expanding the premium instrument base 12%. Operating margin hit 28.9%, lifting EPS to $3.08, up 18%. Momentum carries into 2026 guidance of $4.63B-$4.72B revenue and $14.29-$14.80 EPS. Execution shines.
8-K
IDEXX CEO succession announced
IDEXX announced CEO transition: Mazelsky steps down May 12, 2026, becoming Executive Chair until retiring post-2027 shareholder meeting; Mike Erickson, current EVP of Global Point of Care Diagnostics, assumes CEO role with deep internal experience. Mazelsky aids seamless handover. Smooth leadership shift planned.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
CODX
Co-Diagnostics, Inc.
0.25-0.02
CRL
Charles River Laboratories Inte
195.22-2.93
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LH
Labcorp Holdings Inc.
258.11-5.22
NEOG
Neogen Corporation
7.04+0.19
WAT
Waters Corporation
378.53-6.89